An interventional study of Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System in Iliac Artery Stenosis and Iliac Artery Occlusion, sponsored by Biotyx Medical (Shenzhen) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by Biotyx Medical (Shenzhen) Co., Ltd. (part of LifeTech Scientific Corporation) · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.
Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 54th largest by planned enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2025, is one of 48 with no phase, reaches primary completion later than 30 of the 39 other live ones, and was the 73rd registered.
457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.
Browse Constriction, Pathologic studies →37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 40+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Xin Lou · Sites in China
Ages 18–90
The Second Hospital of Anhui Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 72 across 296 interventional studies indexed under Constriction, Pathologic.
Median enrollment 145 across the 56 interventional studies, 400 across the 25 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 81 have an industry lead sponsor. The 10 most frequent:
This study is registered under Biotyx Medical (Shenzhen) Co., Ltd., one of the names counted as LifeTech Scientific Corporation. Under that name alone:
Biotyx Medical (Shenzhen) Co., Ltd. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
LifeTech Scientific Corporation has 3 studies filed under Constriction, Pathologic — fewer than ten, so there is no comparison to draw.
15 of the studies in Constriction, Pathologic with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07197970Phase 3Beijing Tiantan HospitalDrug- Eluting Stent for Symptomatic Intracranial Arterial Stenosis | 2027-05-15 |
| NCT07542938Xuanwu Hospital, BeijingMedeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis | 2026-11-30 |
| NCT07462546General Hospital of Shenyang Military RegionTranscranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS) | 2026-11-30 |
| NCT06503692DK Medical Technology (Suzhou) Co., Ltd.Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis | 2026-12 |
| NCT06539689FrontAce Scientific Co., LtdA Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries | 2026-12-04 |
Add all 15 to your calendar (.ics) → With an account.
Among the 81 studies in Constriction, Pathologic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a prospective, single-center, first-in-man clinical trial to evaluate the feasibility, preliminary safety and effectiveness of the Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System. 15 subjects are intended to be enrolled.
Clinical follow-up visits should be conducted at before discharge, 30 days, 6 month, 9 months, and 12 months post-procedure. CTA and DUS will be performed at 6 month and 12 months post-procedure.
The primary endpoints include primary patency rate of the target lesion at 12 months post-procedure and Major Adverse Events (MAE) at 9 months post-procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General inclusion criteria
Angiographic Inclusion Criteria
Exclusion Criteria:
General exclusion criteria
Angiographic Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System
Device: Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System
Subjects in the arm will be treated with ICS-Elpis
Primary Efficacy Endpoint: Primary Patency Rate of the Target Lesion
Primary patency is defined as the peak systolic velocity ratio (PSVR) ≤2.4 assessed by duplex ultrasonography (DUS) or the stenosis degree of the target lesion≤70% assessed by CTA; if there is a conflict between the results of DUS and CTA, the CTA result should prevail.
Time frame: At12 months
Primary Safety Endpoint: Rate of Major Adverse Events
The endpoint is a composite endpoint includes 1. Device or procedure-related death within 30 days 2. Myocardial Infarction (MI) within 30 days, 3. Target lesion revascularization (TLR) within 9 months, 4. Major amputation above the ankle joint of the target limb, resulting from a vascular event within 9 months.
Time frame: At 30 days (for death and MI) and 9 months (for TLR and major amputation)
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Dec 2027, 23 months later.
Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 23 months is below that.
Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biotyx Medical (Shenzhen) Co., Ltd. →